Physician profile
Christopher Moreno
NPI 1275196784
$2,203.66
in general payments reported to CMS, 2019-2025
21 companies · $731 in 2025
The $731 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $122 · 2022: $257 · 2023: $499 · 2024: $473 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $417.31 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $250.92 | 2022-2025 | Ilumya, Odomzo |
| Abbvie INC. | $243.21 | 2022-2025 | |
| Lilly USA, LLC | $168.80 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $154.87 | 2022-2025 | Adbry |
| Pfizer INC. | $140.84 | 2024-2025 | |
| Genentech USA, INC. | $122.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $112.84 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $109.58 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $88.69 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $64.04 | 2022-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.20 | 2023-2025 | Siliq, Jublia, Cabtreo |
| Ucb, INC. | $47.55 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Organon LLC | $32.69 | 2025 | Vtama |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $31.31 | 2025 | Seysara |
| Dermavant Sciences, INC. | $30.62 | 2023-2024 | Vtama |
| Incyte Corporation | $29.03 | 2023-2024 | Opzelura |
| Biofrontera INC. | $24.83 | 2025 | Ameluz |
| Arcutis Biotherapeutics, INC. | $18.44 | 2025 | Zoryve |
| Krystal Biotech INC | $14.70 | 2025 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.